Natixis Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$1.34M Buy
42,508
+2,117
+5% +$66.7K ﹤0.01% 1210
2025
Q1
$1.32M Buy
40,391
+1,324
+3% +$43.4K ﹤0.01% 1200
2024
Q4
$1.41M Sell
39,067
-251
-0.6% -$9.08K ﹤0.01% 1203
2024
Q3
$1.23M Buy
39,318
+5,113
+15% +$159K ﹤0.01% 1233
2024
Q2
$915K Sell
34,205
-3,676
-10% -$98.3K ﹤0.01% 1282
2024
Q1
$1.29M Buy
37,881
+1,122
+3% +$38.3K ﹤0.01% 1148
2023
Q4
$1.06M Buy
36,759
+1,081
+3% +$31.3K ﹤0.01% 1188
2023
Q3
$984K Buy
35,678
+1,647
+5% +$45.4K ﹤0.01% 1179
2023
Q2
$1.02M Sell
34,031
-2,713
-7% -$81.6K ﹤0.01% 1151
2023
Q1
$1.33M Buy
36,744
+1,194
+3% +$43.3K ﹤0.01% 1067
2022
Q4
$1.27M Buy
35,550
+755
+2% +$26.9K ﹤0.01% 1068
2022
Q3
$1.18M Buy
34,795
+1,497
+4% +$50.7K 0.01% 1056
2022
Q2
$963K Buy
33,298
+2,172
+7% +$62.8K ﹤0.01% 1140
2022
Q1
$1.01M Buy
31,126
+4,129
+15% +$133K ﹤0.01% 1132
2021
Q4
$787K Buy
26,997
+4,953
+22% +$144K ﹤0.01% 1161
2021
Q3
$588K Buy
22,044
+2,419
+12% +$64.5K ﹤0.01% 1186
2021
Q2
$604K Buy
19,625
+3,525
+22% +$108K ﹤0.01% 1187
2021
Q1
$421K Sell
16,100
-96
-0.6% -$2.51K ﹤0.01% 1190
2020
Q4
$407K Buy
16,196
+3,774
+30% +$94.8K ﹤0.01% 1145
2020
Q3
$259K Sell
12,422
-1,623
-12% -$33.8K ﹤0.01% 1120
2020
Q2
$334K Buy
+14,045
New +$334K ﹤0.01% 1115
2020
Q1
Sell
-52,152
Closed -$1.24M 1224
2019
Q4
$1.24M Sell
52,152
-12,793
-20% -$303K 0.01% 937
2019
Q3
$1.79M Sell
64,945
-14,932
-19% -$410K 0.01% 799
2019
Q2
$2.64M Buy
+79,877
New +$2.64M 0.02% 686
2016
Q4
Sell
-25,746
Closed -$637K 1038
2016
Q3
$637K Buy
25,746
+2,045
+9% +$50.6K 0.01% 874
2016
Q2
$483K Buy
+23,701
New +$483K 0.01% 890